Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.61 |
| ▸ | MME | P08473 | 1/20 | 0.61 |
| ▸ | CPA1 | P15085 | 1/20 | 0.61 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.61 |
| ▸ | PPARA | Q07869 | 3/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.55 |
| ▸ | PPARG | P37231 | 2/20 | 0.54 |
| ▸ | CTSS | P25774 | 7/20 | 0.51 |
| ▸ | CTSK | P43235 | 5/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.49 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28310184 | 0.91 | KLK5 (0.54) | ACEMMECPA1ACE2PPARA | |
| SCHEMBL2583495 | 0.91 | KLK5 (0.54) | ACEMMECPA1ACE2PPARA | |
| SCHEMBL7720051 | 0.88 | ACE (0.54) | ACEMMECPA1ACE2PPARA | |
| SCHEMBL1023002 | 0.87 | ACE (0.54) | ACEMMECPA1ACE2PPARA | |
| SCHEMBL19155424 | 0.87 | PPARA (0.53) | ACEMMECPA1ACE2PPARA | |
| SCHEMBL23780715 | 0.87 | PPARA (0.53) | ACEMMECPA1ACE2PPARA | |
| SCHEMBL1023004 | 0.87 | ACE (0.54) | ACEMMECPA1ACE2PPARA | |
| SCHEMBL28956926 | 0.86 | PTPN1 (0.54) | ACEMMECPA1ACE2PPARA | |
| SCHEMBL30874994 | 0.86 | JAK3 (0.52) | ACEMMECPA1ACE2PPARA | |
| SCHEMBL22143903 | 0.86 | ACE (0.52) | ACEMMECPA1ACE2PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893634-B1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-12-21 | — | — | EP | disclosed |
| US-8048881-B2 | Uding 4-aminocarbonyl-pyrimidine; vascular disorders; cardiovascular disorders; thrombosis; brain disorders; vision defects | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-11-01 | — | — | US | disclosed |
| US-20080194576-A1 | Pyrimidine Derivatives and Their Use as P2Y12 Receptor Antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-08-14 | — | — | US | disclosed |
| EP-1893634-A2 | PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006114774-A2 | PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194576-A1 | Pyrimidine Derivatives and Their Use as P2Y12 Receptor Antagonists | P2RY12, P2RY13, P2RY4 | ACE 1066/4885MME 3334/4885CPA1 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.